SHIONOGI Group Policy in the fight against doping
Shionogi & Co., Ltd. and its affiliates (collectively “SHIONOGI”, “SHIONOGI Group” or ”We”) supports WADA’s efforts to prevent the abuse of medicines for doping in sport and hereby sets forth its policy, “SHIONOGI Group Policy in the fight against doping,” to contribute to the eradication of the misuse and abuse of medicines for doping.
This Policy refers to the “JOINT DECLARATION ON COOPERATION IN THE FIGHT AGAINST DOPING IN SPORT “, which was signed by the International Federation of Pharmaceutical Manufactures & Associations (IFPMA) and the World Anti-Doping Agency (WADA) in July, 2010, and is also consistent with the statements made in “WADA and IFPMA strengthen collaboration in the protection of clean sport”, which was signed by IFPMA and WADA in July, 2020.
1. Principles of Conduct
The “SHIONOGI Group Code of Conduct” consists of 10 points of commitment and is focused on contributing to the resolution of the health concerns of society and helping to realize a sustainable and healthier society.
We aim to ensure the correct use of SHIONOGI’s healthcare products as a responsible pharmaceutical company, drawing upon the following points of commitment in our Code of Conduct: “1. Sustainable economic growth and the resolution of the health concerns of society,” which reflects our mission to discover and develop original pharmaceutical drugs, to offer comprehensive healthcare solutions, and to provide high-quality, safe, effective and valuable healthcare products and services through innovation and “8. Involvement in our communities and contribution to their development,” which shows our intention to contribute to the sustainable development of our local communities, as well as of the international community.
The SHIONOGI Group hopes that athletes will maintain their health and play sports under fair conditions. We would like to fulfill our social responsibilities as a pharmaceutical company through our support of WADA’s anti-doping efforts, which includes sharing information on compounds under development.
2. Collaboration with WADA to evaluate the doping potential of compounds in Research and Development
SHIONOGI group consistently pursues the research and development of innovative and reliable pharmaceutical products based on SHIONOGI Group Heritage: “SHIONOGI strives constantly to supply the best possible medicine to protect the health and wellbeing of the patients we serve”.
SHIONOGI Group has implemented a system to evaluate the doping effect of compounds in R&D in accordance with the guidelines* published by WADA and IFPMA. We will seek to identify any doping potential of our compounds and develop testing methods to detect illegal use, in order to prevent the abuse of SHIONOGI’s development compounds and to help to ensure that athletes will maintain their health and play sports under fair conditions.
June 22, 2021
Shionogi & Co., Ltd.
Representative Director and President and CEO